Denali Therapeutics has raised more than $248 million in its stock market debut, marking the largest biotech IPO of the year. The company will use the cash to support work on its experimental drugs for Parkinson’s disease and other neurodegenerative disorders.... Read more »
Sam Isaly, managing partner of OrbiMed Advisors, is stepping down from the company. OrbiMed, a leading healthcare investment firm founded by Isaly, made the announcement Thursday, two days after Stat published a report of sexual harassment allegations from former OrbiMed employees... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
Rahul Chaturvedi worked for 16 years as a life sciences company executive, but he was also an avid consumer tech fan who chafed at the clunky enterprise apps used in his industry. Spoiled by speedy, user-friendly consumer apps, he also wondered... Read more »
Sage Therapeutics disclosed another clinical trial victory this morning, sending shares of the Cambridge, MA, company to new highs. An experimental Sage drug for major depressive disorder (MDD), a psychiatric disease that affects millions of Americans, has succeeded in a Phase... Read more »
Want to take part in an interactive, constructive talk about what can be done, right now, to alter the course of the life sciences scene in New York? You’ve still got a shot.
Next Monday evening, Dec. 11, at the... Read more »
It’s time to catch up on the latest Boston-area tech headlines:
—People can now ride around Boston’s Seaport neighborhood in a self-driving vehicle, thanks to a pilot program launched this week by ride-hailing company Lyft and NuTonomy, the autonomous vehicle software... Read more »
Healthcare investment giant OrbiMed Advisors has been described as a workplace enveloped in a toxic culture of sexual harassment, according to an investigation by Stat released late Tuesday.
OrbiMed managing partner and co-founder Samuel Isaly is the main perpetrator of frequent... Read more »
[Updated 12/8/17, 4:27 pm. See below.] Boston-area cybersecurity startup Lexumo has shut down, a source close to the company confirmed to Xconomy.
After publication, CEO Dan McCall confirmed the news in an e-mail to Xconomy that said Lexumo ceased... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease, rare blood disorders, and more. With part two, we’re... Read more »
They embrace the unfamiliar, overcome adversity, and through it all, make the most of limited resources. These characteristics describe many entrepreneurs. But they also describe immigrants, says Noubar Afeyan, CEO of Cambridge, MA, venture capital firm Flagship Pioneering.
It’s no coincidence... Read more »
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing.
As remarkable as they might seem, however, these medicines... Read more »